Fu Mengxia, Li Yanping, Wang Jian
Galactophore Department, Galactophore Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Department of Gastrointestinal Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
J Gastroenterol Hepatol. 2025 May;40(5):1143-1156. doi: 10.1111/jgh.16910. Epub 2025 Feb 28.
Colorectal cancer is an escalating public health concern in Asia, characterized by unique epidemiological patterns.
We analyzed colorectal cancer data from 47 Asian countries using GLOBOCAN 2022. Spearman's correlation assessed the relationship between the Human Development Index and cancer rates. Projections for 2050 incidence and mortality were based on demographic forecasts.
In 2022, Asia accounted for 50.2% of global colorectal cancer cases, with 966.4 thousand new cases and 462.3 thousand deaths, including 10% in younger individuals. Age-standardized rates of incidence and mortality were 15.6/100 000 and 7.1/100 000, respectively. Incidence rates were rising faster in younger and male individuals. A significant correlation was found between the Human Development Index and cancer rates. Japan had the highest incidence rate (45.5/100 000 males; 28.5/100 000 females), and Brunei Darussalam had the highest mortality rate (21/100 000 males; 13.9/100 000 females). China recorded the highest incidence and mortality counts, with 307.7 thousand new cases and 142.6 thousand deaths in males, and 209.4 thousand new cases and 97.4 thousand deaths in females. By 2050, 1.87 million new cases and 1.01 million deaths are expected to occur in Asia, with the largest relative increases occurring in low HDI countries.
These findings highlight the need for targeted policies in low HDI countries, focusing on public awareness, early detection, prevention, and improving healthcare infrastructure. Interventions for younger individuals and males are also essential to address rising incidence rates.
结直肠癌在亚洲对公众健康的威胁日益严重,具有独特的流行病学模式。
我们使用GLOBOCAN 2022分析了47个亚洲国家的结直肠癌数据。Spearman相关性分析评估了人类发展指数与癌症发病率之间的关系。2050年发病率和死亡率的预测基于人口预测。
2022年,亚洲占全球结直肠癌病例的50.2%,新增病例96.64万例,死亡46.23万例,其中10%为年轻患者。年龄标准化发病率和死亡率分别为15.6/10万和7.1/10万。年轻个体和男性的发病率上升更快。人类发展指数与癌症发病率之间存在显著相关性。日本的发病率最高(男性为45.5/10万;女性为28.5/10万),文莱达鲁萨兰国的死亡率最高(男性为21/10万;女性为13.9/10万)。中国的发病率和死亡人数最高,男性新增病例30.77万例,死亡14.26万例,女性新增病例20.94万例,死亡9.74万例。到2050年,预计亚洲将有187万新增病例和101万例死亡,低人类发展指数国家的相对增幅最大。
这些发现凸显了低人类发展指数国家制定针对性政策的必要性,重点是提高公众意识、早期检测、预防和改善医疗基础设施。针对年轻个体和男性的干预措施对于应对发病率上升也至关重要。